Transaction #24130 · Form 4 · 0001628280-25-058506
SUPERNUS PHARMACEUTICALS, INC. · Exercise / conversion · Common Stock
SUPERNUS PHARMACEUTICALS, INC. · Transacted December 19, 2025 · Filed December 22, 2025
What does this filing report?
An SEC Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. records an exercise / conversion involving Common Stock on December 19, 2025. The reported quantity was 5,000. The filing date is December 22, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001356576
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 5,000
- Reported price
- 39.4
- Reference value
- 197,000
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 20,496
- Ownership description
- Not reported
- SEC acceptance time
- Dec 22, 2025, 4:04 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Mottola Frank ↗
SVP, Chief Tech. Ops. Officer
CIK 0001804567
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025.
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.39. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F3
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.69. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F4
- The option vests in four equal annual installments beginning on February 14, 2019 .
- F5
- The option vests in four equal annual installments beginning on February 24, 2018.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.